IABS

What IABS does

IABS — International Alliance for Biological Standardization — is an independent, non-profit scientific alliance founded in 1955 and headquartered in Geneva, Switzerland, with regional affiliates in Lyon (IABS-EU, declared under French Loi 1901, 2014) and Palm Springs (IABS-NA, US Section 501(c)(3), EIN 33-0840743). Its core function is to convene regulators, industry scientists, and academic experts on a neutral platform to develop consensus recommendations for the science, regulation, and standardization of human and veterinary vaccines, biotherapeutics, and other biological products. The organization runs roughly seven to nine international scientific conferences and workshops annually across topics including NGS, HPAI, real-world evidence, controlled human infection models, statistics, and African swine fever, and publishes the peer-reviewed journal Biologicals through Elsevier (celebrating its 50th anniversary in 2023).

The business model is event-driven and diversified across five revenue streams: tiered conference registration (industry $1,100–1,500; academia/government €300–500; graduate students free), annual membership dues providing voting rights and reduced journal subscription rates, Elsevier royalties on Biologicals, corporate sponsorships (Pfizer, BMS, Amgen, Kite Pharma, Zoetis, Biowest, PathoQuest have sponsored events), and tax-deductible donations processed via Donorbox (US) and HelloAsso (France). IABS also acts as the public-partner consortium lead or member on multi-year EU/CEPI-funded research projects including MUSICC, Inno4Vac, ZAPI, VAC2VAC, DRIVE, and ASFAVIP, and operates the Actors4Health endowment fund established in 2021. The organization is governed by its Constitution under Articles 60-79 of the Swiss Civil Code, with regional affiliate Boards and a global leadership team (Shawn Novick, President; Olivier Espeisse, IABS-EU President; Dean Smith, IABS-NA President).

Name

IABS

Legal name

International Alliance for Biological Standardization

Website

https://iabs.org

Company type

Private

Founded year

1955

Operating status

Operating

Headcount range

251–500 employees

Short description

IABS is an independent, non-profit scientific alliance founded in 1955 that convenes regulators, industry, and academia across 50+ countries to develop consensus on the regulation and standardization of human and veterinary vaccines and biotherapeutics. It delivers this through international conferences, the Elsevier journal Biologicals, and EU/CEPI-funded research consortia.

Ownership category

akta.pro rank

Product category

Regulatory Science & Biological Standardization Services

NAICS

Professional Organizations (81392), Business Associations (813910)

SIC

Services-Membership Organizations (8600), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Immunization & Vaccine Access Alliances (HLAJAKAK)

Keywords

• Scientific conferences
• Regulatory science
• Biological standardization
• Vaccine workshops
• Biologics collaboration

Headquarters

HQ city

Geneva

HQ country

Switzerland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Conference Registration Fees: Revenue generated from registration fees for workshops and conferences. Graduate students attend free, academia/government attendees pay reduced rates (€300-500), and industry participants pay full rates (€1,100-1,500).
2. Membership Dues: Annual membership dues assessed at the beginning of each calendar year, providing voting rights and reduced journal subscription rates.
3. Journal Biologicals Royalties: Reports and proceedings of IABS conferences appear in the journal Biologicals, published by Elsevier, generating royalty revenue.
4. Donations and Fundraising: Tax-deductible donations from individuals, institutions, and foundations supporting the development and improvement of human and veterinary biological therapies and vaccines. US-based donations through Donorbox, France-based through HelloAsso.
5. Conference Sponsorships: Corporate sponsorships for specific conferences and workshops, with organizations like Kite Pharma, Pfizer, BMS, Amgen, Biowest, Zoetis, and PathoQuest sponsoring events.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

IABS is an independent, non-profit scientific alliance that organizes international conferences and workshops bringing together regulators, industry, and academia to advance the science, regulation, and standardization of vaccines, biotherapeutics, and other biological products. It publishes the peer-reviewed journal Biologicals, manages collaborative research projects on vaccine development, and offers membership services. Founded in 1955 and headquartered in Geneva, it operates through regional affiliates IABS-EU (Lyon, France) and IABS-NA (Palm Springs, USA).

Product overview

IABS (International Alliance for Biological Standardization) is an independent, non-profit scientific alliance that serves as a neutral platform for collaboration on the science, regulation, and standardization of vaccines, biotherapeutics, and other biological products. The organization operates through three core offerings: (1) international scientific conferences and workshops that foster dialogue among scientists, regulators, and industry professionals; (2) the peer-reviewed journal Biologicals published by Elsevier; and (3) collaborative research projects including MUSICC, Inno4Vac, VAC2VAC, ZAPI, and ASFAVIP addressing specific challenges in biological product development. The organization also offers membership services and manages the Actors4Health endowment fund for donations supporting global health initiatives.

Differentiator

Problem solved

Functional benefit

Brands

• Actors4Health: Endowment fund established in 2021 for donors who would become eligible for tax reduction within Europe. The fund receives donations from private persons and organizations, with an independent scientific committee deciding on allocation of funding.

Products and services

• IABS Scientific Conferences and Workshops International scientific conferences and workshops bringing together regulators, industry leaders, and academic experts to discuss the science, regulation, and standardization of vaccines, biotherapeutics, and other biological products.
• Biologicals Journal

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core and minor.

• MUSICC (Mucosal Immunity in Human Coronavirus Challenge)coreStrategic or Co-development PartnerInternational research project laying groundwork for next-generation COVID-19 vaccines that could prevent infection and transmission. Led by Imperial College London, co-funded by European Union's Horizon Europe Programme and CEPI. Conducts controlled human infection studies to understand mucosal immunity.
• Inno4Vac (Innovations to Accelerate Vaccine Development and Manufacture)coreStrategic or Co-development PartnerPublic-private partnership addressing scientific bottlenecks in vaccine development through predictive biological and mathematical models. IABS-EU drives the regulatory part of the project. Part of European collaborative efforts to accelerate vaccine manufacturing.
• ZAPI (Zoonoses Anticipation and Preparedness Initiative)coreStrategic or Co-development PartnerPart of IMI public-private partnership, aims to enable swift response to major new infectious disease threats by designing new manufacturing processes for vaccines, antibodies, and antibody-like molecules against zoonotic diseases with pandemic potential.
• VAC2VACcoreStrategic or Co-development PartnerCollaborative research project funded by IMI2 developing and validating quality testing approaches for human and veterinary vaccines using non-animal methods. Supports 3Rs principles (Replace, Reduce, Refine animal testing).
• DRIVE (Development of Robust and Innovation Vaccine Effectiveness)minorStrategic or Co-development PartnerPublic-private partnership advancing European cooperation in influenza vaccine effectiveness studies. Establishes network for brand-specific effectiveness estimates and sustainable governance model for public-private partnerships.
• Imperial College LondoncoreStrategic or Co-development PartnerLeads the MUSICC project for next-generation coronavirus vaccine development through controlled human infection studies.
• WOAH (World Organisation for Animal Health)coreStrategic or Co-development PartnerMoU renewed during 92nd WOAH General Session. Collaboration on biological standardization for animal health and vaccines. WOAH includes foetal blood as 'safe commodity' in revised guidelines.
• CEPI (Coalition for Epidemic Preparedness Innovations)coreStrategic or Co-development PartnerCo-funder of MUSICC project. IABS collaborates with CEPI on vaccine development priorities and regulatory advisory groups during pandemics.
• IMI (Innovative Medicines Initiative)coreStrategic or Co-development PartnerEuropean public-private partnership speeding development of better and safer medicines. IABS-EU part of consortia selected as public partners for ZAPI, VAC2VAC, and other projects.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• International Society for Pharmaceutical Engineering (ISPE): Member-driven organization for pharma engineering and manufacturing science, hosting conferences and publishing guidance — comparable to IABS in its standards-setting and event-driven nonprofit model.
• International Council for Harmonisation (ICH): Multi-stakeholder body producing harmonized regulatory guidelines for pharmaceuticals; closely aligned with IABS's mission to advance regulatory science through consensus.
• Parenteral Drug Association (PDA): Membership organization for pharmaceutical and biologics manufacturing professionals, producing technical reports, conferences, and training on quality standards — overlapping IABS's biologicals standardization work.
• Drug Information Association (DIA): Global neutral member organization running conferences and training on regulatory science, drug development, and healthcare product regulation — directly overlapping IABS's conference and consensus-building mission.

Broad incumbents

• BIO (Biotechnology Innovation Organization): Large biotech industry association hosting the BIO Convention and convening regulators/industry globally — broader portfolio but overlapping in vaccine and biologicals policy convening.

Others

• Wellcome Trust: Major global health funder supporting vaccine R&D and pandemic preparedness; thematic peer as a parallel funder-convenor in the same ecosystem as IABS's MUSICC and Inno4Vac work.

Emerging players

• American Society of Gene & Cell Therapy (ASGCT): Member society hosting conferences and policy advocacy on advanced therapies; relevant peer as IABS expands into cell therapy (e.g., 2027 Barcelona Flow Cytometry workshop).
• Coalition for Epidemic Preparedness Innovations (CEPI): Public-private coalition funding vaccine development against epidemic threats; a co-funder of MUSICC and a strategic partner overlapping IABS's vaccine standardization mission.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCu4bFoT11QdeZuhR2ExA-_Q
• LinkedInlinkedin.com/company/international-alliance-for-biological-standardization---iabs
• Xx.com/IABS_Global

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IABS